For context on what untreated full-retail pricing means at population scale, peer-reviewed estimates put annual per-person GLP-1 spending at roughly $12,022
Personalized treatment plan Based on your evaluation, we create a customized weight loss strategy that includes your GLP-1 medication, dosing schedule, nutrition guidance, and a timeline for follow-up appointments
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
Improved mitochondrial function translates to better cellular energy production, which can have cascading benefits across various physiological systems
GLP-1 receptor agonists overview. Davies M, et al
Rather than drawing at random times, experienced researchers draw at the same time on the same days
